At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Curcumin plus Piperinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study
In Brief
A Phase 2 clinical trial evaluating Curcumin plus Piperine for Prostate Cancer and 3 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Multiple Myeloma, Smoldering Multiple Myeloma (SMM), Monoclonal Gammopathy of Undetermined Significance
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartDec 2021
Primary CompletionSep 2024
TodayJul 2026
First PostedFeb 1, 2021
Enrollment StartDec 14, 2021
Primary CompletionSep 19, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.4 years ago
Interventions
Curcumin plus Piperinedrug
Curcumin with piperine is a well-tolerated over-the-counter supplement.